{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T13:44:22Z","timestamp":1782308662817,"version":"3.54.5"},"reference-count":77,"publisher":"Informa UK Limited","issue":"4","license":[{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"GSK funded this project"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Biological Therapy"],"published-print":{"date-parts":[[2025,4,3]]},"DOI":"10.1080\/14712598.2025.2479018","type":"journal-article","created":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T12:00:41Z","timestamp":1742472041000},"page":"425-435","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Belimumab patient profile in Spain: evolution during the last decade and future directions"],"prefix":"10.1080","volume":"25","author":[{"given":"Tarek Carlos","family":"Salman-Monte","sequence":"first","affiliation":[{"name":"Hospital del Mar-IMIM","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jos\u00e9","family":"Cuadrado","sequence":"additional","affiliation":[{"name":"Cl\u00ednica Universidad de Navarra","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Galindo","sequence":"additional","affiliation":[{"name":"Hospital Universitario 12 de Octubre","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Espinosa","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednic","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Morales","sequence":"additional","affiliation":[{"name":"Hospital Universitario 12 de Octubre","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Mar\u00eda","family":"Pego-Reigosa","sequence":"additional","affiliation":[{"name":"Complejo Hospitalario Universitario de Vigo","place":["Pontevedra, Spain"]},{"name":"IRIDIS (Investigation in Rheumatology and Immune-Mediated Diseases)-Vigo Group, Galicia Sur Health Research Institute","place":["Vigo, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucio","family":"Pallar\u00e9s","sequence":"additional","affiliation":[{"name":"Hospital Universitari Son Espases","place":["Palma de Mallorca, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Covadonga","family":"L\u00f3pez","sequence":"additional","affiliation":[{"name":"GSK","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"San Rom\u00e1n","sequence":"additional","affiliation":[{"name":"GSK","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00cd\u00f1igo","family":"R\u00faa-Figueroa","sequence":"additional","affiliation":[{"name":"Hospital Universitario de Gran Canaria Doctor Negr\u00edn","place":["Las Palmas de Gran Canaria, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,3,20]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cden.2013.06.003"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2009.12.008"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2023-eular.6101"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfv381"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2022.03.016"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2011.04.032"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt.13.107"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nefro.2022.12.008"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar2506"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-017-1442-6"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI38010"},{"key":"e_1_3_5_14_1","unstructured":"Benlysta. Summary of product characteristics [Internet]. [cited 2024 Feb 29]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/benlysta-epar-product-information_en.pdf"},{"key":"e_1_3_5_15_1","unstructured":"Benlysta (BEL). US prescribing information [Internet]. [cited 2024 Feb 29]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/125370s062%2C761043s002lbl.pdf"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24699"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.980079"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1177\/09612033211028653"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.3390\/jpm13040691"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-017-3682-9"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-016-0047-x"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.4414\/smw.2019.20022"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2015-000118"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1177\/0961203320947814"},{"key":"e_1_3_5_25_1","unstructured":"AEMPS. Ficha T\u00e9cnica Benlysta [internet]. [cited 2024 Feb 29]. Available from: https:\/\/cima.aemps.es\/cima\/pdfs\/es\/ft\/11700001\/FT_11700001.html.pdf"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nefroe.2023.05.006"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.reuma.2013.04.001"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rce.2012.10.004"},{"key":"e_1_3_5_29_1","unstructured":"Ministerio de Sanidad. Servicios Sociales e Igualdad. Gu\u00eda de Pr\u00e1ctica Cl\u00ednica sobre Lupus Eritematoso Sist\u00e9mico [Internet]. [cited 2024 Feb 29]. Available from: https:\/\/portal.guiasalud.es\/wp-content\/uploads\/2020\/10\/gpc_549_lupus_sescs_compl_caduc.pdf"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215089"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224762"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.06.019"},{"key":"e_1_3_5_33_1","unstructured":"KDIGO. Clinical practice guideline for the management of LUPUS NEPHRITIS - Kidney international [Internet]. [2024 [cited 2024 Feb 29]. Available from: https:\/\/www.kidney-international.org\/article\/S0085-2538(23)00627-0\/fulltext"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-022-06287-9"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.reuma.2022.08.001"},{"key":"e_1_3_5_36_1","first-page":"773","article-title":"IF086 \u2013 BEL en el lupus eritematoso sist\u00e9mico","volume":"216","author":"S\u00e1nchez Herrera M","year":"2016","unstructured":"S\u00e1nchez Herrera M, Rodr\u00edguez JA, Esteban Marcos E, et al. IF086 \u2013 BEL en el lupus eritematoso sist\u00e9mico. Rev Clin Esp. 2016;216:773.","journal-title":"Rev Clin Esp"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-eular.7530"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1177\/0961203319835320"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.5152\/eurjrheum.2019.17169"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2020.12.036"},{"key":"e_1_3_5_41_1","unstructured":"Piqueras Garc\u00eda M Ferna\u00e1ndez Guill E Egea Fuentes A et al. Uso Del F\u00e1rmaco Belimumab En Un Hospital De Tercer Nivel. May 10\u201313."},{"key":"e_1_3_5_42_1","first-page":"17","article-title":"Eficacia cl\u00ednica con Belimumab en pacientes con lupus eritematoso sist\u00e9mico en \u00e1rea de gesti\u00f3n sanitaria norte de C\u00e1diz","author":"Almansa Ram\u00edrez \u00c1","year":"2021","unstructured":"Almansa Ram\u00edrez \u00c1, Serrano Virl\u00e1n C, Pastor Mena M, et al. Eficacia cl\u00ednica con Belimumab en pacientes con lupus eritematoso sist\u00e9mico en \u00e1rea de gesti\u00f3n sanitaria norte de C\u00e1diz. Reumatolog\u00eda Cl\u00ednica. 2021:17.","journal-title":"Reumatolog\u00eda Cl\u00ednica"},{"key":"e_1_3_5_43_1","first-page":"4","article-title":"Efectividad y seguridad con Belimumab, en pacientes con LES: estudio en vida real","volume":"8","author":"Rosas G\u00f3mez de Salazar JC","year":"2023","unstructured":"Rosas G\u00f3mez de Salazar JC, Pons Bas A, Santos Soler G, et al. Efectividad y seguridad con Belimumab, en pacientes con LES: estudio en vida real. Revista de la SVR: Soc Valenciana de Reumatolog\u00eda. 2023;8:4\u201310.","journal-title":"Revista de la SVR: Soc Valenciana de Reumatolog\u00eda"},{"key":"e_1_3_5_44_1","unstructured":"Frag\u00edo Gill J Mat\u00ednez Calabuig P Salvador Maicas L et al. P-40: Belimumab para el tratamiento del lupus eritematoso sist\u00e9mico: Datos de vida real. 2023."},{"key":"e_1_3_5_45_1","unstructured":"De la Rubia Navarro M Ivorra Cort\u00e9s J Grau Garc\u00eda E et al Experiencia cl\u00ednica del tratamiento con belimumab en pacientes con lupus eritematoso sist\u00e9mico en un hospital terciario. [Internet]. Sociedad Valenciana de Reumatolog\u00eda; 2020. Available at: https:\/\/svreumatologia.es\/wp-content\/uploads\/2020\/09\/svr-congresos-xxiii-congreso-svr-septiembre-2020-poster-32-lupus-eritematoso-sistemico.pdf"},{"key":"e_1_3_5_46_1","first-page":"A1","article-title":"LP-191\u2005Baseline profile of systemic lupus erythematosus patients on treatment with belimumab of a Spanish multicenter cohort","volume":"10","author":"Altab\u00e1s-Gonz\u00e1lez I","year":"2023","unstructured":"Altab\u00e1s-Gonz\u00e1lez I, Pego-Reigosa JM, Mouri\u00f1o-Rodr\u00edguez C, et al. LP-191\u2005Baseline profile of systemic lupus erythematosus patients on treatment with belimumab of a Spanish multicenter cohort. Lupus Sci Med. 2023;10:A1\u2013171.","journal-title":"Lupus Sci Med"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead159"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2023-eular.3482"},{"key":"e_1_3_5_49_1","unstructured":"Aldasoro V Lai\u00f1o M Enguita M et al. 0350: Spanish national registry of Belimumab in patients with systemic lupus erythematosus [Internet]. 2022 [cited 2024 Feb 29]. Available from: https:\/\/www.eventscribe.net\/2022\/ACRConvergence\/fsPopup.asp?Mode=presInfo&PresentationID=1128451"},{"key":"e_1_3_5_50_1","article-title":"Spanish national registry of belimumab in patients with systemic lupus erythematosus","volume":"75","author":"Lai\u00f1o M","year":"2023","unstructured":"Lai\u00f1o M, Enguita M, Loricera J, et al. Spanish national registry of belimumab in patients with systemic lupus erythematosus. Arthritis Rheumatol. 2023;75(s10).","journal-title":"Arthritis Rheumatol"},{"key":"e_1_3_5_51_1","unstructured":"Espinosa G R\u00edos R Barilaro G et al. #1605 - Eficacia Y Seguridad De Belimumab En La Cohorte BELILES-GEAS [Internet]. 2023 [cited 2024 Mar 1]. Available from: https:\/\/congresosemi.com\/site\/programme\/?1=1&sessiondetail=4571388&abstractdetail=149804&a=semi2023&trackid=0&i=#!"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1177\/09612033241237560"},{"key":"e_1_3_5_53_1","first-page":"451","article-title":"P409 \u2013 Respuesta humoral tras la vacunaci\u00f3n frente a COVID-19 en pacientes con enfermedades autoinmunes en tratamiento con rituximab y BEL","volume":"19","author":"J\u00fadez Navarro E","year":"2023","unstructured":"J\u00fadez Navarro E, Cebrian L, S\u00e1nchez Nievas G, et al. P409 \u2013 Respuesta humoral tras la vacunaci\u00f3n frente a COVID-19 en pacientes con enfermedades autoinmunes en tratamiento con rituximab y BEL. Reumatol Clin. 2023;19:451.","journal-title":"Reumatol Clin"},{"key":"e_1_3_5_54_1","first-page":"27","article-title":"CO30 \u2013 Respuesta a la vacunaci\u00f3n para SARS-CoV-2 en pacientes reum\u00e1ticos y neurol\u00f3gicos tratados con distintas terapias inmunosupresoras","volume":"19","author":"Ugena Garc\u00eda R","year":"2023","unstructured":"Ugena Garc\u00eda R, Calomarde G\u00f3mez C, Valera J, et al. CO30 \u2013 Respuesta a la vacunaci\u00f3n para SARS-CoV-2 en pacientes reum\u00e1ticos y neurol\u00f3gicos tratados con distintas terapias inmunosupresoras. Reumatol Clin. 2023;19:27\u201328.","journal-title":"Reumatol Clin"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2014.08.1703"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S218464"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.02520322"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfad063c_3858"},{"key":"e_1_3_5_59_1","first-page":"56","article-title":"194 - Experiencia con Belimumab en Nefropat\u00eda L\u00fapica. A Prop\u00f3sito de Cuatro Casos","volume":"43","author":"Padros Soler M","year":"2023","unstructured":"Padros Soler M, Salmer\u00f3n Rodr\u00edguez M, Villegas P\u00e9rez I, et al. 194 - Experiencia con Belimumab en Nefropat\u00eda L\u00fapica. A Prop\u00f3sito de Cuatro Casos. Nefrologia. 2023;43:56.","journal-title":"Nefrologia"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2022.05.003"},{"key":"e_1_3_5_61_1","first-page":"89","article-title":"RC63. Belimumab para el tratamiento del lupus eritematoso sist\u00e9mico: datos de vida real","volume":"19","author":"Fragio Gil JJ","year":"2023","unstructured":"Fragio Gil JJ, Martinez Calabuig P, Salvador Maicas L, et al. RC63. Belimumab para el tratamiento del lupus eritematoso sist\u00e9mico: datos de vida real. Reumatol Clin. 2023;19:89\u201390","journal-title":"Reumatol Clin"},{"key":"e_1_3_5_62_1","first-page":"75","article-title":"Lupus nephritis of the Spanish national registry of belimumab in patients with systemic lupus erythematosus","author":"Lai\u00f1o M","year":"2023","unstructured":"Lai\u00f1o M, Enguita M, Navarro P, et al. Lupus nephritis of the Spanish national registry of belimumab in patients with systemic lupus erythematosus. Arthritis Rheumatol. 2023:75","journal-title":"Arthritis Rheumatol"},{"key":"e_1_3_5_63_1","first-page":"60","article-title":"213 - Uso de Belimumab en la Nefritis L\u00fapica (NL). Experiencia en nuestro centro","volume":"43","author":"Marrero Robayna S","year":"2023","unstructured":"Marrero Robayna S, Gonz\u00e1lez Cabrera F, Santana Quintana A, et al. 213 - Uso de Belimumab en la Nefritis L\u00fapica (NL). Experiencia en nuestro centro. Nefrologia. 2023;43:60.","journal-title":"Nefrologia"},{"key":"e_1_3_5_64_1","unstructured":"Garc\u00eda Garc\u00eda J P\u00e9rez Suarez G L\u00f3pez Martel D et al. 186 - Tratamiento de la nefritis l\u00fapica con Belimumab: serie de casos. 2023;43:54."},{"key":"e_1_3_5_65_1","unstructured":"Asociaci\u00f3n Andaluza de Enfermedades Autoinmunes y la Sociedad Andaluza de Nefrolog\u00eda. Cuadernos de Autoinmunidad: Monogr\u00e1fico Nefritis L\u00fapica [Internet]. 2024. Available from: https:\/\/sademi.com\/resources\/files\/Cuadernos%20Autoinmunidad%20Ano16.%20Monografico%20Nefritis%20Lupica%202024_compressed_compressed.pdf"},{"key":"e_1_3_5_66_1","unstructured":"Morales E Cuadrado MJ Espinosa G et al. Evoluci\u00f3n del perfil de paciente con nefritis l\u00fapica tratado con belimumab en Espa\u00f1a. 54 Congreso de la Sociedad Espa\u00f1ola de Nefrolog\u00eda. 2024"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.41253"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2022.2096406"},{"key":"e_1_3_5_69_1","article-title":"Health outcomes among patients (pts) with SLE initiating belimumab (BEL) with and without the use of immunosuppressants in the previous 2 years","volume":"75","author":"Chen Y","year":"2023","unstructured":"Chen Y, Worley K, Rabideau B, et al. Health outcomes among patients (pts) with SLE initiating belimumab (BEL) with and without the use of immunosuppressants in the previous 2 years. Arthritis Rheumatol. 2023;75(s10).","journal-title":"Arthritis Rheumatol"},{"key":"e_1_3_5_70_1","article-title":"Introduction of belimumab within five years of the onset of systemic lupus erythematosus (SLE) contributes to the better therapeutic response; a multi-center retrospective cohort study","volume":"75","author":"Kojima K","year":"2023","unstructured":"Kojima K, Ichinose K, Shimizu T, et al. Introduction of belimumab within five years of the onset of systemic lupus erythematosus (SLE) contributes to the better therapeutic response; a multi-center retrospective cohort study. Arthritis Rheumatol. 2023;75(s9). Available from: https:\/\/acrabstracts.org\/abstract\/introduction-of-belimumab-within-five-years-of-the-onset-of-systemic-lupus-erythematosus-sle-contributes-to-the-better-therapeutic-response-a-multi-center-retrospective-cohort-study\/.","journal-title":"Arthritis Rheumatol"},{"key":"e_1_3_5_71_1","article-title":"Cumulative infections by week 52 among patients with SLE: a summary of data from placebo-controlled belimumab studies","volume":"75","author":"Sheikh S","year":"2023","unstructured":"Sheikh S, Withrop K, Yazdany J, et al. Cumulative infections by week 52 among patients with SLE: a summary of data from placebo-controlled belimumab studies. Arthritis Rheumatol [Internet]. 2023 [cited 2024 Mar 4];75. Available from: https:\/\/acrabstracts.org\/abstract\/cumulative-infections-by-week-52-among-patients-with-sle-a-summary-of-data-from-placebo-controlled-belimumab-studies\/","journal-title":"Arthritis Rheumatol [Internet]"},{"key":"e_1_3_5_72_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.42620"},{"key":"e_1_3_5_73_1","article-title":"P119- Infecci\u00f3n Grave Y COVID-19 En Pacientes Tratados Con Belimumab En Una Amplia Cohorte Multic\u00e9ntrica Espa\u00f1ola De Pacientes Con Les, En Situaci\u00f3n De Pr\u00e1ctica Cl\u00ednica Real","volume":"19","author":"R\u00faa-Figueroa I","year":"2023","unstructured":"R\u00faa-Figueroa I, Altab\u00e1s-Gonz\u00e1lez I, Jim\u00e9nez Otero N, et al. P119- Infecci\u00f3n Grave Y COVID-19 En Pacientes Tratados Con Belimumab En Una Amplia Cohorte Multic\u00e9ntrica Espa\u00f1ola De Pacientes Con Les, En Situaci\u00f3n De Pr\u00e1ctica Cl\u00ednica Real. Reumatol Clin. 2023;19(S1):S119.","journal-title":"Reumatol Clin"},{"key":"e_1_3_5_74_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2017.1324784"},{"key":"e_1_3_5_75_1","doi-asserted-by":"publisher","DOI":"10.31138\/mjr.28.1.4"},{"key":"e_1_3_5_76_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218272"},{"key":"e_1_3_5_77_1","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2021-000634"},{"key":"e_1_3_5_78_1","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2023-001124"},{"key":"e_1_3_5_79_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-020-00243-2"}],"container-title":["Expert Opinion on Biological Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2025.2479018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T06:20:58Z","timestamp":1744179658000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14712598.2025.2479018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,20]]},"references-count":77,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4,3]]}},"alternative-id":["10.1080\/14712598.2025.2479018"],"URL":"https:\/\/doi.org\/10.1080\/14712598.2025.2479018","relation":{},"ISSN":["1471-2598","1744-7682"],"issn-type":[{"value":"1471-2598","type":"print"},{"value":"1744-7682","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,20]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-11-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}